We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Thermo Fisher Scientific completes acquisition of Life Technologies

Thermo Fisher Scientific completes acquisition of Life Technologies

February 5, 2014
CenterWatch Staff

Thermo Fisher Scientific has completed its acquisition of Life Technologies for $13.6 billion ($76.13 in cash per fully diluted common share), plus the assumption of $1.5 billion in net debt. The completion of the transaction follows the receipt of all required regulatory approvals.

"Our combined offering provides cutting-edge technologies, such as genomics and proteomics, to accelerate life sciences research and improve human health,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. β€œAnd our complementary strengths in biosciences and bioprocessing will accelerate drug discovery, development and production. With the addition of Life Technologies, we are in an even stronger position to help our customers achieve their goals for innovation and productivity."

With the acquisition, Thermo Fisher has established a new reporting segment, called Life Sciences Solutions. Mark Stevenson, who was CEO of Life Technologies, has been named an executive vice president and president of Life Sciences Solutions, reporting directly to Casper.

The new Life Sciences Solutions Segment will consist of the majority of the former Life Technologies and Thermo Fisher Biosciences businesses. Thermo Fisher's Global Chemicals business will move from the Biosciences business to the Laboratory Products and Services Segment. Thermo Fisher's Analytical Technologies Segment will be renamed Analytical Instruments to reflect the transfer of the Biosciences businesses. Two small specialty diagnostics businesses within Life Technologies will become part of the Specialty Diagnostics Segment. Thermo Fisher has agreed to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare for $1.06 billion.

Global News CROs/Service Providers

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development β€” PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases β€” PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing